$DEVS
DevvStream Corp.

2025 Q1 Form 10-Q Financial Statement

#000114036125001804 Filed on January 23, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.373M
YoY Change -44.78%
Operating Profit -$1.373M
YoY Change -44.78%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $401.7K
YoY Change -53.81%
Pretax Income -$970.8K
YoY Change -39.93%
Income Tax $40.92K
% Of Pretax Income
Net Earnings -$1.012M
YoY Change -42.87%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 28.34M
Diluted Shares Outstanding

Balance Sheet

Concept 2025 Q1 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $8.469K
Receivables
Other Receivables
Total Short-Term Assets $207.9K
YoY Change -19.04%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $19.31M
YoY Change -68.63%
TOTAL ASSETS
Total Short-Term Assets $207.9K
Total Long-Term Assets $19.31M
Total Assets $19.51M
YoY Change -68.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.85M
YoY Change 88.94%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.85M
Total Long-Term Liabilities
Total Liabilities $13.68M
YoY Change 56.05%
SHAREHOLDERS EQUITY
Retained Earnings -$13.65M
YoY Change 60.34%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.65M
YoY Change
Total Liabilities & Shareholders Equity $19.51M
YoY Change -68.42%

Cashflow Statement

Concept 2025 Q1 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.012M
YoY Change -42.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001854480
devs Number Of Days Prior In Initial Business Combination
NumberOfDaysPriorInInitialBusinessCombination
P2D
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
devs Period To File Registration Statement
PeriodToFileRegistrationStatement
P20D
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
DEVVSTREAM CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A0
dei Entity File Number
EntityFileNumber
001-40977
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2433757
dei Entity Address Address Line1
EntityAddressAddressLine1
2108 N St., Suite 4254
dei Entity Address City Or Town
EntityAddressCityOrTown
Sacramento
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95816
dei City Area Code
CityAreaCode
818
dei Local Phone Number
LocalPhoneNumber
683-2765
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Focus Impact Acquisition Corp.
dei Security12b Title
Security12bTitle
Common shares
dei Trading Symbol
TradingSymbol
DEVS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28343067
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
13937
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8469
CY2024Q3 devs Redemption Payable Current
RedemptionPayableCurrent
0
CY2023Q4 devs Redemption Payable Current
RedemptionPayableCurrent
43640022
CY2024Q3 devs Marketing Agreement Noncurrent
MarketingAgreementNoncurrent
150000
CY2023Q4 devs Marketing Agreement Noncurrent
MarketingAgreementNoncurrent
150000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1372525
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2485780
us-gaap Operating Expenses
OperatingExpenses
4065418
us-gaap Operating Expenses
OperatingExpenses
4027550
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1372525
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2485780
us-gaap Operating Income Loss
OperatingIncomeLoss
-4065418
us-gaap Operating Income Loss
OperatingIncomeLoss
-4027550
CY2024Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
227000
CY2023Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-227000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-227000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-681000
CY2024Q3 devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
0
CY2023Q3 devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
309534
devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
0
devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
309534
CY2024Q3 devs Operating Account Interest Income
OperatingAccountInterestIncome
116
CY2023Q3 devs Operating Account Interest Income
OperatingAccountInterestIncome
2434
devs Operating Account Interest Income
OperatingAccountInterestIncome
1479
devs Operating Account Interest Income
OperatingAccountInterestIncome
13363
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
174594
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
784704
us-gaap Investment Income Interest
InvestmentIncomeInterest
644756
us-gaap Investment Income Interest
InvestmentIncomeInterest
4604705
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
401710
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
869672
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
419235
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4246602
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-970815
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1616108
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3646183
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
219052
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40918
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154799
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
217448
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
938294
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1011733
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1770907
us-gaap Net Income Loss
NetIncomeLoss
-3863631
us-gaap Net Income Loss
NetIncomeLoss
-719242
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9159694
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2234269
CY2024Q1 devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
220115
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-11614078
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-617629
CY2024Q2 devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
213978
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-12445685
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1011733
CY2024Q3 devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
191347
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-13648765
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9955210
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1522559
CY2023Q1 devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
1961604
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-10394255
CY2023Q2 devs Excise Tax Payable In Connection With Redemptions
ExciseTaxPayableInConnectionWithRedemptions
-1798606
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-470894
CY2023Q2 devs Extension Funding Of Trust Account
ExtensionFundingOfTrustAccount
487500
CY2023Q2 devs Remeasurement Adjustment Of Class A Common Stock To Redemption Amount
RemeasurementAdjustmentOfClassACommonStockToRedemptionAmount
-811227
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-13962482
CY2023Q3 devs Waiver Of Deferred Underwriters Fee
WaiverOfDeferredUnderwritersFee
8340466
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1770907
CY2023Q3 devs Extension Funding Of Trust Account
ExtensionFundingOfTrustAccount
487500
CY2023Q3 devs Remeasurement Adjustment Of Class A Common Stock To Redemption Amount
RemeasurementAdjustmentOfClassACommonStockToRedemptionAmount
-631704
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-8512127
us-gaap Net Income Loss
NetIncomeLoss
-3863631
us-gaap Net Income Loss
NetIncomeLoss
-719242
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
227000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
681000
devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
0
devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
309534
us-gaap Investment Income Interest
InvestmentIncomeInterest
644756
us-gaap Investment Income Interest
InvestmentIncomeInterest
4604705
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4378
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-323705
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2875313
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2731643
devs Increase Decrease In Franchise Tax Payable
IncreaseDecreaseInFranchiseTaxPayable
-10134
devs Increase Decrease In Franchise Tax Payable
IncreaseDecreaseInFranchiseTaxPayable
-33303
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
90000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
90000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-157636
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-639735
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1488222
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2480171
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
975000
devs Trust Extension Funding
TrustExtensionFunding
343516
devs Trust Extension Funding
TrustExtensionFunding
0
devs Cash Withdrawal From Trust Account In Connection With Redemptions
CashWithdrawalFromTrustAccountInConnectionWithRedemptions
43640022
devs Cash Withdrawal From Trust Account In Connection With Redemptions
CashWithdrawalFromTrustAccountInConnectionWithRedemptions
179860588
devs Cash Withdrawn From Trust Account To Pay Taxes Obligation
CashWithdrawnFromTrustAccountToPayTaxesObligation
535219
devs Cash Withdrawn From Trust Account To Pay Taxes Obligation
CashWithdrawnFromTrustAccountToPayTaxesObligation
1217500
devs Return Of Excess Withdrawals For Taxes
ReturnOfExcessWithdrawalsForTaxes
75773
devs Return Of Excess Withdrawals For Taxes
ReturnOfExcessWithdrawalsForTaxes
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43755952
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
180103088
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
43640022
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
179860588
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1100000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1025000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-42540022
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-178835588
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-272292
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1212671
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300167
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1426006
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27875
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213335
devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
625440
devs Redeemable Common Stock Accretion To Redemption Value
RedeemableCommonStockAccretionToRedemptionValue
4379535
devs Redeemable Of Excise Tax Payable In Connection
RedeemableOfExciseTaxPayableInConnection
0
devs Redeemable Of Excise Tax Payable In Connection
RedeemableOfExciseTaxPayableInConnection
1798606
devs Impact Of Waiver Of Deferred Commission By Underwriters
ImpactOfWaiverOfDeferredCommissionByUnderwriters
0
devs Impact Of Waiver Of Deferred Commission By Underwriters
ImpactOfWaiverOfDeferredCommissionByUnderwriters
8340466
devs Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1
devs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
devs Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1
devs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
devs Period Of Extension To Consummate Business Combination
PeriodOfExtensionToConsummateBusinessCombination
P1M
devs Period Of Advance Notice To Consummate Initial Business Combination
PeriodOfAdvanceNoticeToConsummateInitialBusinessCombination
P5D
devs Period Of Additional Charter Extension Date
PeriodOfAdditionalCharterExtensionDate
P12M
CY2023Q2 devs Redemption Limitation Amendment Proposal Amount
RedemptionLimitationAmendmentProposalAmount
5000000
devs Number Of Business Days
NumberOfBusinessDays
P10D
CY2023Q2 devs Lenders Contribution Deposited In Trust Account
LendersContributionDepositedInTrustAccount
162500
CY2023Q2 devs Lenders Contribution Deposited In Trust Account Amount Per Share
LendersContributionDepositedInTrustAccountAmountPerShare
0.0325
devs Period Of Extension To Consummate Business Combination
PeriodOfExtensionToConsummateBusinessCombination
P1M
CY2023Q2 devs Additional Payments To Acquire Marketable Securities
AdditionalPaymentsToAcquireMarketableSecurities
1300000
devs Period Of Extension To Consummate Business Combination
PeriodOfExtensionToConsummateBusinessCombination
P1M
devs Period Of Advance Notice To Consummate Initial Business Combination
PeriodOfAdvanceNoticeToConsummateInitialBusinessCombination
P5D
CY2023Q4 devs Period Of Additional Charter Extension Date
PeriodOfAdditionalCharterExtensionDate
P10M
CY2023Q4 devs Lenders Contribution Deposited In Trust Account
LendersContributionDepositedInTrustAccount
40000
CY2023Q4 devs Lenders Contribution Deposited In Trust Account Amount Per Share
LendersContributionDepositedInTrustAccountAmountPerShare
0.02
devs Period Of Extension To Consummate Business Combination
PeriodOfExtensionToConsummateBusinessCombination
P1M
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
25843
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
75773
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
75773
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
25843
CY2023Q2 devs Class Of Warrant Or Right Redemption Price
ClassOfWarrantOrRightRedemptionPrice
1
CY2023Q4 devs Minimum Number Of Public Holders Required For Continued Listing
MinimumNumberOfPublicHoldersRequiredForContinuedListing
400
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Use of Estimates</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of the condensed consolidated financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div>
CY2024Q3 us-gaap Cash
Cash
2032
CY2023Q4 us-gaap Cash
Cash
224394
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
25843
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
75773
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
us-gaap Derivatives Methods Of Accounting Nonhedging Derivatives
DerivativesMethodsOfAccountingNonhedgingDerivatives
<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Warrant Liability</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </span> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company accounted for the 22,700,000 warrants issued in connection with the IPO and Private Placement in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at fair value and will adjust the instrument to fair value at each reporting period. This liability will be re-measured at each balance sheet date until the warrants are exercised or expire, and any change in fair value will be recognized in the Company’s condensed consolidated statement of operations. The fair value of privately-held warrants was estimated using an internal valuation model. Our valuation model utilized inputs such as assumed share prices, volatility, discount factors and other assumptions and may not be reflective of the price at which they can be settled. Such warrant classification is also subject to re-evaluation at each reporting period. <br/> </span> </div>
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0421
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0958
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0596
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
4.2834
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
4064
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 devs Funds Withdrawn From Trust Account Reserved To Payment Of Taxes
FundsWithdrawnFromTrustAccountReservedToPaymentOfTaxes
75773
devs Period To Exercise Warrants After Public Offerings
PeriodToExerciseWarrantsAfterPublicOfferings
P12M
devs Period Required For Warrants To Become Exercisable
PeriodRequiredForWarrantsToBecomeExercisable
P30D
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
devs Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
P60D
devs Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
P60D
CY2021Q4 devs Product Value Issued Upon Exercise Of Warrants
ProductValueIssuedUponExerciseOfWarrants
0.361
devs Number Of Trading Days
NumberOfTradingDays
P10D
CY2024Q3 devs Funds Withdrawn From Trust Account Reserved To Payment Of Taxes
FundsWithdrawnFromTrustAccountReservedToPaymentOfTaxes
25843
CY2023Q4 devs Funds Withdrawn From Trust Account Reserved To Payment Of Taxes
FundsWithdrawnFromTrustAccountReservedToPaymentOfTaxes
75773
CY2021Q4 devs Underwriting Fees Deferred
UnderwritingFeesDeferred
8650000
CY2023Q3 devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
309534
CY2023Q3 devs Waiver Of Deferred Underwriters Fee
WaiverOfDeferredUnderwritersFee
8340466
CY2024Q3 devs Underwriting Fees Deferred
UnderwritingFeesDeferred
0
CY2023Q4 devs Underwriting Fees Deferred
UnderwritingFeesDeferred
0
CY2024Q3 devs Underwriting Fees Deferred
UnderwritingFeesDeferred
0
CY2023Q3 devs Recovery Of Offering Costs Allocated To Warrants
RecoveryOfOfferingCostsAllocatedToWarrants
309534
devs Stock Conversion Ratio
StockConversionRatio
1
CY2024Q3 devs Stock Conversion As Converted Percentage
StockConversionAsConvertedPercentage
0.20
devs Trust Extension Funding
TrustExtensionFunding
1643516
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Cash
Cash
2032
CY2023Q4 us-gaap Cash
Cash
224394
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
25843
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
75773
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
171573
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
19307014
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
62418210
CY2024Q3 us-gaap Assets
Assets
19514931
CY2023Q4 us-gaap Assets
Assets
62736405
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7283393
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4408080
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
330000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
240000
CY2024Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
29896
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
40030
CY2024Q3 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
2235006
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
2235006
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2975000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1875000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12853295
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52438138
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
681000
CY2024Q3 us-gaap Liabilities
Liabilities
13684295
CY2023Q4 us-gaap Liabilities
Liabilities
53042138
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
19479401
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
18853961
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13649340
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9160269
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-13648765
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9159694
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19514931
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62736405
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4091
CY2024Q3 us-gaap Assets Current
AssetsCurrent
207917
CY2023Q4 us-gaap Assets Current
AssetsCurrent
318195
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
454000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align: justify; color: rgb(0, 0, 0);"> <span style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Concentration of Credit Risk</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/> Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. As of September 30, 2024 and December 31, 2023, the Company had not experienced losses on this account and management believes the Company was not exposed to significant risks on such account.</div>
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0

Files In Submission

Name View Source Status
0001140361-25-001804-index-headers.html Edgar Link pending
0001140361-25-001804-index.html Edgar Link pending
0001140361-25-001804.txt Edgar Link pending
0001140361-25-001804-xbrl.zip Edgar Link pending
devs-20240930.xsd Edgar Link pending
devs-20240930_def.xml Edgar Link unprocessable
devs-20240930_pre.xml Edgar Link unprocessable
ef20034578_10q.htm Edgar Link pending
ef20034578_ex10-4.htm Edgar Link pending
ef20034578_ex31-1.htm Edgar Link pending
ef20034578_ex31-2.htm Edgar Link pending
ef20034578_ex32-1.htm Edgar Link pending
ef20034578_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
ef20034578_10q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
devs-20240930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
devs-20240930_lab.xml Edgar Link unprocessable